Background: Spinal metastases of lung cancer (SMLC) usually have a high degree of malignancy and require multimodality treatment. Patients with SMLC who experience clinical symptoms (eg, local pain, emerging or potential spinal instability, and progressive neurological dysfunction) require surgical treatment. However, there are discrepancies in the comparison of outcomes between surgical treatment and nonsurgical treatment.
Objective: This paper presents the protocol for a study that aims to compare the clinical outcomes of surgical treatment and nonsurgical treatment for SMLC, explore the prognostic factors of SMLC, and establish a survival prediction model based on these prognostic factors.
Methods: This is a prospective cohort study, with an anticipated sample size of 240 patients (120 patients in the surgical group and 120 patients in the nonsurgical group). We will collect baseline data, including demographic, clinical, and radiological information, as well as data from patient-reported questionnaires. Patients will be followed up at 3, 6, 12, and 24 months after treatment, and survival status will be assessed every 3 months. The primary outcome is the overall survival period. Prognostic factors associated with overall survival will be analyzed by univariate and multivariate Cox proportional hazards regression. Odds ratios with 95% CIs will be presented. Statistical significance is set at P<.05.
Results: This study has been approved by our institute’s Medical Science Research Ethics Committee (IRB00006761-M2021085) after a careful audit of the design and content. Patient enrollment began in June 2022 at our hospital. Data collection is expected to be completed by early 2026, and the study results will be published by mid-2027.
Conclusions: In this study, we propose to set up a prospective cohort of patients with SMLC to investigate the outcomes between surgical treatment and nonsurgical treatment. We will explore the role of surgical treatment in SMLC and provide guidance to peer surgeons.
Trial Registration: Chinese Clinical Trial Registry, ChiCTR2100048151; http://www.chictr.org.cn/showproj.aspx?proj=129450
International Registered Report Identifier (IRRID): DERR1-10.2196/38273
The effective integration of therapeutic modalities into the treatment of metastatic lung cancer on the spine is a source of debate. Lung cancer is a moderate to high malignancy, and metastasis to the spine usually represents the end stage of the disease [, ]. According to the scoring systems for spinal metastasis by Tomita et al [ ] and Tokuhashi et al [ ], patients with spinal metastases of lung cancer (SMLC) are expected to live less than 1 year. Thus, more conservative treatments have been given in the past. In recent years, advances in radiation therapy and systemic antitumor drugs, such as stereotactic body radiotherapy (SBRT), target therapies, and immunological therapies have demonstrated encouraging therapeutic outcomes and have largely expanded the survival time of patients with SMLC [ - ]. At the same time, surgical treatment has been widely accepted for some SMLC cases [ ]. A comprehensive treatment, composed of antitumor drugs, radiotherapy, and surgery, has been the current state-of-the-art therapeutic modality for SMLC.
Generally, patients with SMLC experiencing the following symptoms are referred for surgery: severe and refractory local pain, emerging or potential spinal instability, and progressive neurological dysfunction [, - ]. After the surgery, adjuvant therapies, including radiotherapy and systemic drugs, are undertaken. Most researchers have stated that adjuvant radiotherapy should be completed around 6 weeks after the operation to spare time for physical recovery and avoid problems related to wound healing [ ]; yet, this is difficult to do in a real-world setting [ ]. Additionally, previous studies have described discrepancies in the efficacy of surgical treatment for patients with SMLC [ ]. According to these works, the median survival time after surgery was reported to range from 2 to 14 months [ ]. Because of limitations that included a retrospective study design, no control group, etc, the conclusions of related studies lack high-quality evidence.
In our study, a prospective, specific disease cohort of SMLC will be used to compare the effectiveness of surgical treatment and nonsurgical treatment. This study will provide useful information to explore the role of surgical treatment in comprehensive SMLC treatment and develop suitable treatment guidelines.
The primary aim of this study is to investigate and compare treatment outcomes in patients with SMLC. In addition, we also plan to analyze various prognostic factors of SMLC, such as treatment modalities, tumor subtypes, pre- and postoperative neurological function, and more.
This study is a prospective cohort study. We will compare the treatment outcomes of surgical and nonsurgical methods for SMLC in a real-world clinical scenario. The study will enroll 240 patients (120 patients in the surgical group and 120 patients in the nonsurgical group) from June 1, 2022, to June 30, 2027. The patients will be visited postoperatively at 3, 6, 12, and 24 months. The study is due to be completed on June 30, 2029.
Sample Size and Study Timeline
In this study, we plan to compare the overall survival (OS) time between the two groups and explore its prognostic factors. The sample size calculation was based on the survival time and estimation of influencing factors. According to an unpublished retrospective study performed at our center and previous literature [, ], the average OS time was 11 (SD 4) months in the surgical group and 9 (SD 3) months in the nonsurgical group. Assuming an overall Type 1 error (α) of .05 and Type II error (β) of .1, we need 66 patients in each group. Additionally, there are 12 predictive factors we plan to analyze in the prediction model. According to the sample size estimation method for multivariable regression models, 100 cases in each group are needed (the ratio of surgical to nonsurgical group is 1:1). Considering a final follow-up rate of 80%, a minimum of 120 patients will be required for each group. There were approximately 25 patients undergoing surgery per year at our center; therefore, we plan to enroll the patients over the next 5 years. Since more patients are treated nonsurgically than surgically, all nonsurgical patients treated during the first 5 years will be enrolled.
The study duration is estimated to be 7 years to ensure that all recruited patients are followed up for 2 years. Each visit’s timeline and tasks are presented in.
Patient Enrollment and Group Allocation
All patients with SMLC being treated at our center are potential candidates, and those who meet the inclusion and exclusion criteria will be eligible for enrollment in our study. Patients who receive surgical treatment along with postoperative systemic comprehensive treatment will be enrolled in the surgical group. Patients who receive only conservative treatment (eg, radiotherapy, chemotherapy, targeted molecular therapy, immunological therapy, etc) without surgical treatment will be enrolled in the nonsurgical group. All study procedures, as well as the participants’ rights, responsibilities, benefits, and risks, will be communicated, and participants will sign an informed consent form.displays the study flowchart.
In order to participate, patients will need to meet certain eligibility criteria. The inclusion criteria are (1) a pathological diagnosis of SMLC, (2) understanding and voluntarily participating in the study, and (3) being regularly followed up beyond 2 years or to the endpoint. Exclusion criteria include: (1) not receiving antitumor treatment at our hospital, (2) coexistence of spinal trauma or infection, (3) history of other malignancies, and (4) unwillingness to participate or inability to adhere to our follow-up schedule.
A surgical decision is made following the advice of our institutional multidisciplinary treatment team for spinal metastasis. There are 3 indications for surgery at our center: severe yet drug-resistant local pain, progressive neurological dysfunction, and emerging or latent spinal instability. Otherwise, patients are referred for nonsurgical treatment.
In the surgical group, patients are given surgical treatment, neurological rehabilitation, and adjuvant therapies (ie, SBRT and antitumor drugs). In this setting, we have established a synchronized workflow for surgery-based multimodality therapy instead of the conventional step-by-step schedule. A synchronized workflow means that neurological rehabilitation is incorporated and commenced right before the surgery and that SBRT and antitumor drugs are started early and simultaneously during the process of rehabilitation.
In the nonsurgical treatment group, patients are treated with adjuvant therapies exclusively, including radiotherapy, chemotherapy, targeted therapy, immunological therapy, etc. Considering the existence of various adjuvant modalities, this study will only enroll patients who receive both locoregional radiotherapy and antitumor drugs.
The primary outcome metric of the study is the OS period. OS is defined as the time after the start of any antitumor therapy for SMLC to death of any cause.
Secondary outcomes include the following:
- The progress-free survival period, defined as the time after the start of antitumor therapies until disease progression.
- Recovery of SMLC-related symptoms, defined as the relief of locoregional pain, which is measured by visual analogue scale (VAS) values, and the recovery of neurological status, which is assessed using the American Spinal Injury Association (ASIA) score. Immediate improvement in VAS and ASIA scores is assessed before discharge.
- Recovery of self-care performance, assessed using the Karnofsky Performance Scale (KPS) score and the Eastern Cooperative Oncology Group (ECOG) performance score.
- Quality of daily life, assessed by the Short Form 36 Health Survey Questionnaire.
Other outcomes for evaluation include complications in antitumor treatment. Surgical complications are rated according to the system proposed by Clavien et al , whereas toxicity of radiotherapy and antitumor drugs is graded using the National Cancer Institute’s Common Toxicity Criteria for Adverse Events (version 5.0). The endpoint of the study is the death of the recruited patient. The primary outcome is assessed by the endpoint of the study, whereas secondary and other outcome metrics are assessed at each visit.
The exposure measures of interest include demographic variables, clinical data, and treatment-related factors. Demographic variables include age, gender, height, weight, and ethnicity. Clinical data are composed of health care factors (comorbidity, smoking status, family history of tumors); tumor factors (pathology, gene detection, tumor segments, and metastatic status); radiological variables (computerized tomography, magnetic resonance imaging, x-ray, positron emission tomography–computerized tomography, and degree of epidural spinal cord compression); and clinical variables, which include onset time, general status (KPS, ECOG score), neurological function (ASIA score), pain (VAS value), and ambulatory status. Treatment-related factors include operation approach, operation time, blood loss, postoperative hospital stay, adjuvant therapies, etc.
Data Management and Supervision
We will assign a specific investigation team to assess outcomes and process the data, and train the team in this regard. In addition, we will formulate some basic rules for the process of patient follow-up; outcomes assessment; and data entry, coding, and storage, namely double assessment, dual entry, and checks by independent investigators. Outcome assessors will be blinded to the patients’ intervention allocation. Our institute’s scientific research supervising team, which excludes all investigators in this study, will monitor the study process, data safety and authenticity, and occurrence of adverse events.
Statistical analysis will be performed using SPSS for Windows (version 20; IBM Corp). The Lilliefors test will be used to examine whether the data are normally distributed. Data will be presented as percentages, mean (SD), or median (range) accordingly. The 1-tailed unpaired Student t test and Pearson χ2 test (or the Fisher exact test) will be used to make comparisons between different groups. The OS and progress-free survival curves will be plotted using the Kaplan-Meier method, and a comparison of the two groups will be performed via the log-rank test. The influencing factors will be analyzed by univariate and multivariate Cox proportional hazards regression. Statistical significance is set at P<.05. The survival prediction model will be established by multivariate Cox regression models and the Kaplan-Meier survival curves. The predictive ability of the final model will be evaluated using the Harrell concordance index (C-index) and calibration curves.
This study, which will be conducted according to the Declaration of Helsinki, has been approved by the Medical Science Research Ethics Committee of the Peking University Third Hospital (IRB00006761-M2021085) after a careful audit of the design and content.
Informed Consent and Funding
We will fully inform the patients of the purpose and procedures of this study, as well as their obligations and potential costs and risks. An informed consent form has been drafted and will be signed voluntarily by each participant.
This study is a self-organized project and receives no financial support or funding from any commercial entity. Therefore, conduct of the study, data processing, and interpretation of the results will not be influenced by any commercial entity.
Study design, ethical review, and research registration have been completed. Enrollment commenced in June 2022, and enrolled patients are being visited regularly. Patient enrollment is expected to be completed by June 2027, and the study results will be submitted for publication in early 2029.
We anticipate that the findings of our cohort study will support the use of a surgical treatment strategy for patients with SMLC. Although we understand that a combination of different antitumor therapies, namely comprehensive treatment, is recommended for patients with SMLC, there is no consensus or established guideline on how to practice it. Our study aims to explore surgery-based comprehensive treatment for patients with SMLC. Through this study, we aim to validate our proposed synchronized schedule for a multimodality therapy and eventually hope to establish a survival prediction model.
Fundamentally, the primary goals of surgery are to restore spinal stability, relieve pain, and decompress tumor mass squeezing of the spinal cord, if any. Yao et al  reviewed studies on spinal metastasis and found that surgery could significantly improve neurological function and quality of life, even for patients with advanced lung cancer. However, we have not yet gained firm evidence on the impact of surgery on patients’ survival, though many papers have reported favorable postoperation outcomes. Truong et al [ ] recruited patients with SMLC undergoing surgery and found that 14 (16%) out of 87 patients survived beyond 12 months. Chen et al [ ] reported the median survival of their cohort to be 12 months; patients undergoing excisional surgery had a longer survival time than those with palliative surgery. Contrarily, in a systematic review by Armstrong et al [ ], the authors reported unfavorable outcomes for surgical intervention, of which a shorter median OS was found in the surgical group compared to the nonsurgical group (7.5 months vs 8.5 months). This result was echoed in Amelot et al’s [ ] study. These authors concluded that survival of SMLC depends merely on genotype and neurological and personal status, and scarcely on surgical resection. In the past decade, the combination of separation surgery and high-dose hypofractionated SBRT has emerged as an effective option for spinal metastasis, including SMLC [ ]. The core principle of this procedure is to circumferentially remove the tumor mass encasing the spinal cord and create a safe zone between the cord and the tumor (≥3mm) for the subsequent delivery of radiation treatment [ , , ].
As our understanding of the molecular biology of lung cancer increases, many mutated targets are being identified, including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, ROS1, BRAF V600E mutation, etc [, , , ]. Targeted drugs can act directly on these specific mutations and diminish tumor cells. Dohzono et al [ ] compared the median OS of patients with SMLC receiving or not receiving EGFR tyrosine kinase inhibitors and found the former group enjoyed a longer OS period (21.4 months vs 6.1 months). In recent years, the application of some immunotherapeutic drugs has proven to be effective [ ]. The concept of immunotherapy is to introduce specific blockers to inhibit some immunological signaling paths that are related to the development and metastasis of tumors. Currently, anti-PD-1 and anti-PD-L1 antibodies have been recognized as the choice of care for some advanced lung cancers after the failure of first-line cytotoxic therapy [ ]. Borghaei et al [ ] found that the median OS period of PD-L1(+) patients who received specific targeted blockers was longer than that of PD-L1(–) patients (17.7 months vs 10.5 months). Furthermore, systematic use of bone-targeted agents (eg, bisphosphonates and denosumab) has significantly reduced devastating spinal-related events, such as paralysis and loss of self-care ability [ ].
Strengths and Limitations
The main strength of our study is that it is the first research project to examine the feasibility and outcomes of synchronized adjuvant therapies after surgical intervention for SMLC in a prospective cohort and using a more scientific methodology. This methodological merit will strongly empower the justification for using positive yet invasive treatment modalities instead of conventional palliative care in patients with SMLC. Second, for the purpose of rapid recovery, we are starting rehabilitative intervention at an early stage after surgery. In addition, we recognize the importance of starting adjuvant therapies early after surgery, and this practice will be implemented and examined in our clinical trial.
There are some potential biases in this study that might compromise the reliability and accuracy of the results, but we have designed some solutions to reduce bias. First, though it is difficult to blind the intervention providers and patients, outcome assessors and data processors will be blinded. Second, during the follow-ups, we will encourage face-to-face interviews, but online interviews will also be accepted, considering the possible emergence of scenarios like a COVID-19 surge, in order to reduce the rate of dropout.
We present the protocol for a prospective cohort study of patients with SMLC. Through this study, we will explore the outcomes of surgery-based comprehensive treatment. In addition, we will also investigate prognostic factors of SMLC and provide references for peer surgeons.
This study was funded by the National Natural Science Foundation of China (82172395).
The data sets generated during and/or analyzed during this study will be available from the corresponding author upon reasonable request.
PH and SZ contributed equally and share the first authorship. FW provided the original concept of the study. PH, SZ, and FW designed the study. PH, SZ, XL, and HC were involved in data collection, follow-up with patients, and statistical analysis. PH and SZ drafted the manuscript. FW and HC critically revised the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript. FW and HC are the study guarantors.
Conflicts of Interest
The visit timeline and list of tasks.DOCX File , 18 KB
- Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 2013 Dec;21(12):3279-3286. [CrossRef] [Medline]
- Cetin K, Christiansen CF, Jacobsen JB, Nørgaard M, Sørensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 2014 Nov;86(2):247-254. [CrossRef] [Medline]
- Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 2001 Feb 01;26(3):298-306. [CrossRef] [Medline]
- Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine 2005 Oct 01;30(19):2186-2191. [CrossRef] [Medline]
- Glicksman RM, Tjong MC, Neves-Junior WFP, Spratt DE, Chua KLM, Mansouri A, et al. Stereotactic ablative radiotherapy for the management of spinal metastases: a review. JAMA Oncol 2020 Apr 01;6(4):567-577. [CrossRef] [Medline]
- Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA 2019 Aug 27;322(8):764-774. [CrossRef] [Medline]
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018 Jan 24;553(7689):446-454. [CrossRef] [Medline]
- Kelly PD, Zuckerman SL, Than KD, Attia A, Jaboin JJ. Metastatic spine disease in lung cancer patients: national patterns of radiation and surgical care. J Spine Surg 2019 Sep;5(3):320-328 [FREE Full text] [CrossRef] [Medline]
- Di Perna G, Cofano F, Mantovani C, Badellino S, Marengo N, Ajello M, et al. Separation surgery for metastatic epidural spinal cord compression: a qualitative review. J Bone Oncol 2020 Dec;25:100320 [FREE Full text] [CrossRef] [Medline]
- Choi SH, Koo JW, Choe D, Kang C. The incidence and management trends of metastatic spinal tumors in South Korea: a nationwide population-based study. Spine (Phila Pa 1976) 2020 Jul 15;45(14):E856-E863. [CrossRef] [Medline]
- Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012 Dec;7(12):1823-1829 [FREE Full text] [CrossRef] [Medline]
- Zhai S, Hu P, Liu X, Li Z, Wang B, Zhou H, et al. Prognostic analysis of spinal metastasis secondary to lung cancer after surgeries: a unicentric, large-cohort, retrospective study. Orthop Surg 2023 Jan;15(1):70-78 [FREE Full text] [CrossRef] [Medline]
- Ha K, Kim YH, Ahn J, Park H. Factors affecting survival in patients undergoing palliative spine surgery for metastatic lung and hepatocellular cancer: dose the type of surgery influence the surgical results for metastatic spine disease? Clin Orthop Surg 2015 Sep;7(3):344-350 [FREE Full text] [CrossRef] [Medline]
- Bakar D, Tanenbaum JE, Phan K, Alentado VJ, Steinmetz MP, Benzel EC, et al. Decompression surgery for spinal metastases: a systematic review. Neurosurg Focus 2016 Aug;41(2):E2. [CrossRef] [Medline]
- Tang Y, Qu J, Wu J, Liu H, Chu T, Xiao J, et al. Effect of surgery on quality of life of patients with spinal metastasis from non-small-cell lung cancer. J Bone Joint Surg Am 2016;98(5):396-402. [CrossRef]
- Park S, Lee C, Chung S. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication. Spine J 2016 Mar;16(3):322-328. [CrossRef] [Medline]
- Truong VT, Shedid D, Al-Shakfa F, Hattou L, Shen J, Boubez G, et al. Surgical intervention for patients with spinal metastasis from lung cancer: a retrospective study of 87 cases. Clin Spine Surg 2021 Apr 01;34(3):E133-E140. [CrossRef] [Medline]
- Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 2013 Mar;18(3):207-214 [FREE Full text] [CrossRef] [Medline]
- Gong Y, Zhuang H, Chong S, Shi Q, Wei F, Liu Z, et al. Delayed postoperative radiotherapy increases the incidence of radiographic local tumor progression before radiotherapy and leads to poor prognosis in spinal metastases. Radiat Oncol 2021 Jan 22;16(1):21 [FREE Full text] [CrossRef] [Medline]
- Yao A, Sarkiss CA, Ladner TR, Jenkins AL. Contemporary spinal oncology treatment paradigms and outcomes for metastatic tumors to the spine: a systematic review of breast, prostate, renal, and lung metastases. J Clin Neurosci 2017 Jul;41:11-23. [CrossRef] [Medline]
- Armstrong V, Schoen N, Madhavan K, Vanni S. A systematic review of interventions and outcomes in lung cancer metastases to the spine. J Clin Neurosci 2019 Apr;62:66-71. [CrossRef] [Medline]
- Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009 Aug;250(2):187-196. [CrossRef] [Medline]
- Chen Q, Chen X, Zhou L, Chen F, Hu A, Wang K, et al. The emergence of new prognostic scores in lung cancer patients with spinal metastasis: a 12-year single-center retrospective study. J Cancer 2021;12(18):5644-5653 [FREE Full text] [CrossRef] [Medline]
- Amelot A, Terrier L, Cristini J, Buffenoir K, Pascal-Moussellard H, Carpentier A, et al. Spinal metastases from lung cancer: survival depends only on genotype, neurological and personal status, scarcely of surgical resection. Surg Oncol 2020 Sep;34:51-56. [CrossRef] [Medline]
- Gong Y, Hu J, Jiang L, Zhuang H, Wei F, Liu Z, et al. What predicts the prognosis of spinal metastases in separation surgery procedures? World Neurosurg 2021 Feb;146:e714-e723. [CrossRef] [Medline]
- Moussazadeh N, Laufer I, Yamada Y, Bilsky MH. Separation surgery for spinal metastases: effect of spinal radiosurgery on surgical treatment goals. Cancer Control 2014 Apr;21(2):168-174 [FREE Full text] [CrossRef] [Medline]
- Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012 Jun 10;30(17):2046-2054. [CrossRef] [Medline]
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015 Oct 22;373(17):1627-1639 [FREE Full text] [CrossRef] [Medline]
- Dohzono S, Sasaoka R, Takamatsu K, Nakamura H. Overall survival and prognostic factors in patients with spinal metastases from lung cancer treated with and without epidermal growth factor receptor tyrosine kinase inhibitors. Int J Clin Oncol 2017 Aug;22(4):698-705. [CrossRef] [Medline]
- Gubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw 2019 May 01;17(5.5):574-578. [CrossRef] [Medline]
- Bozzo A, Deng J, Abbas U, Bhasin R, Deodat M, Wariach S, et al. Which bone-modifying agent is associated with better outcomes in patients with skeletal metastases from lung cancer? A systematic review and network meta-analysis. Clin Orthop Relat Res 2021 Sep 01;479(9):2047-2057 [FREE Full text] [CrossRef] [Medline]
|ASIA: American Spinal Injury Association|
|C-index: concordance index|
|ECOG: Eastern Cooperative Oncology Group|
|EGFR: epidermal growth factor receptor|
|KPS: Karnofsky Performance Scale|
|OS: overall survival|
|SBRT: stereotactic body radiotherapy|
|SMLC: spinal metastases of lung cancer|
|VAS: visual analogue scale|
Edited by G Eysenbach; submitted 26.03.22; peer-reviewed by M Xu, H Long, J Wang; comments to author 18.11.22; revised version received 26.12.22; accepted 12.01.23; published 30.01.23Copyright
©Panpan Hu, Shuheng Zhai, Xiaoxie Liu, Hongling Chu, Feng Wei. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 30.01.2023.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.